Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Several other research firms have also issued reports on KPTI. Robert W. Baird reaffirmed a “positive” rating and issued a $16.00 price objective on shares of Karyopharm Therapeutics in a research note on Tuesday, September 6th. Vetr downgraded Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 price target on the stock. in a report on Wednesday, August 31st. S&P Equity Research reduced their price target on Karyopharm Therapeutics from $9.06 to $7.55 in a report on Tuesday, August 30th. Leerink Swann reiterated an “outperform” rating and issued a $18.00 price target on shares of Karyopharm Therapeutics in a report on Friday, October 7th. Finally, Jefferies Group reiterated a “buy” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a report on Thursday, September 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Karyopharm Therapeutics has an average rating of “Buy” and a consensus target price of $15.47.
Karyopharm Therapeutics (NASDAQ:KPTI) traded down 0.80% during midday trading on Friday, hitting $9.93. The company had a trading volume of 12,267 shares. The stock has a 50 day moving average price of $8.76 and a 200 day moving average price of $8.33. The company’s market capitalization is $409.54 million. Karyopharm Therapeutics has a 52 week low of $4.83 and a 52 week high of $19.41.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.12. Equities analysts forecast that Karyopharm Therapeutics will post ($3.00) earnings per share for the current fiscal year.
In other news, insider Ran Frenkel sold 3,309 shares of Karyopharm Therapeutics stock in a transaction on Monday, November 14th. The stock was sold at an average price of $10.06, for a total value of $33,288.54. Following the transaction, the insider now directly owns 14,691 shares in the company, valued at approximately $147,791.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.79% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the company. BlackRock Advisors LLC boosted its stake in Karyopharm Therapeutics by 15.1% in the third quarter. BlackRock Advisors LLC now owns 11,410 shares of the company’s stock worth $111,000 after buying an additional 1,498 shares during the last quarter. Emerald Acquisition Ltd. boosted its stake in Karyopharm Therapeutics by 46.2% in the third quarter. Emerald Acquisition Ltd. now owns 14,327 shares of the company’s stock worth $139,000 after buying an additional 4,527 shares during the last quarter. Endurance Wealth Management Inc. boosted its stake in Karyopharm Therapeutics by 166.7% in the third quarter. Endurance Wealth Management Inc. now owns 16,000 shares of the company’s stock worth $156,000 after buying an additional 10,000 shares during the last quarter. Bank of Montreal Can acquired a new stake in Karyopharm Therapeutics during the third quarter worth $159,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Karyopharm Therapeutics during the third quarter worth $162,000. 49.20% of the stock is owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.